Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$22.07 USD
+0.98 (4.65%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $22.07 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PCRX 22.07 +0.98(4.65%)
Will PCRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCRX
Is the Options Market Predicting a Spike in Pacira BioSciences Stock?
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say
Pacira (PCRX) Q1 Earnings Surpass Estimates
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
Other News for PCRX
Pacira BioSciences: Worth Pondering, Strong Balance Sheet
Pacira just upgraded at Truist, here's why
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 | PCRX Stock News
Pacira BioSciences (PCRX) Partners with J&J to Boost Zilretta Sales
Pacira signs partnership with JNJ to expand Zilretta